The Surprising Paradox of Remimazolam: Inflammation Without Cognitive Decline?
Perioperative Neurocognitive Disorders (PND), particularly postoperative delirium and cognitive decline, are significant concerns in elderly patients undergoing surgery. These disorders not only hinder recovery and impair self-care but also increase the risk of complications and mortality. While factors like age, comorbidities, and anesthesia techniques contribute to PND, systemic inflammation triggered by surgery and subsequent neuroinflammation are key players. Video-assisted thoracic surgery (VATS), a minimally invasive approach, reduces surgical trauma but doesn't eliminate the risk of PND due to factors like ischemia-reperfusion injury and one-lung ventilation.
Anesthetic management plays a crucial role in mitigating perioperative inflammation. Propofol, a commonly used anesthetic in VATS, exhibits anti-inflammatory properties by suppressing the NF-κB signaling pathway. However, its cardiovascular effects and injection pain limit its use in certain patients. Enter remimazolam, a novel benzodiazepine with minimal circulatory depression, no injection pain, and a specific antagonist (flumazenil). It modulates GABA receptors, potentially reducing cellular apoptosis and offering neuroprotection. But here's where it gets controversial: while some studies suggest remimazolam elevates inflammatory markers without increasing complications, others find no significant difference compared to propofol.
Our study aimed to unravel this paradox. We hypothesized that remimazolam might be less effective than propofol in suppressing early postoperative inflammation in elderly VATS patients, but wouldn't increase PND incidence within 7 days. We conducted a randomized controlled trial, comparing remimazolam and propofol in terms of inflammatory markers, cognitive function, hemodynamic stability, and adverse events.
Results revealed a surprising dichotomy. Remimazolam indeed led to higher levels of CRP, IL-6, leukocyte count, neutrophil count, and SIRI compared to propofol at 24 hours postoperatively, indicating a heightened inflammatory response. However, this increased inflammation didn't translate to worse cognitive outcomes. MMSE scores and 3D-CAM results showed no significant difference between groups, and PND incidence was comparable. And this is the part most people miss: despite elevated systemic inflammation, neuroinflammation markers like S100β remained similar, suggesting a dissociation between systemic and central nervous system inflammation.
Remimazolam also demonstrated significant clinical advantages. It provided more stable hemodynamics, reduced hypotension risk, and offered shorter recovery times compared to propofol. While induction time was longer with remimazolam, it didn't impact PACU stay or clinical efficiency.
This study highlights the complex relationship between inflammation and cognitive function in the perioperative setting. While remimazolam may not be as potent as propofol in suppressing inflammation, its neuroprotective effects and favorable clinical profile make it a promising anesthetic option for elderly VATS patients. However, further research is needed to fully understand the mechanisms underlying its paradoxical inflammatory response and its long-term impact on cognitive function.
Food for thought: Could the transient nature of the inflammatory response with remimazolam be a key factor in preventing PND? Does the lack of central neuroinflammation explain the preserved cognitive function despite systemic inflammation? These questions invite further investigation and debate, encouraging us to delve deeper into the intricate interplay between anesthesia, inflammation, and cognitive health.
